A double-blind, placebo controlled study to assess the safety and preliminary efficacy of PSD506 in treatment-naive or previously treated (washed out) patients with symptoms of overactive bladder (OAB)
Latest Information Update: 27 Jul 2020
At a glance
- Drugs PSD 506 (Primary)
- Indications Overactive bladder
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Plethora Solutions
- 07 Jul 2007 New trial record.